Navigation Links
ACT Secures Patent to Generate Embryonic Stem Cells Without Embryo Destruction

MARLBOROUGH, Mass., Feb. 23, 2011 /PRNewswire/ -- Advanced Cell Technology, Inc. ("ACT"; OTC Bulletin Board: ACTC), a leader in the field of regenerative medicine, announced today that it has been issued a patent on its "single-blastomere" technique.  Patent Number 7,893,315 broadly covers ACT's proprietary single-blastomere technology that provides a non-destructive alternative for deriving human embryonic stem cell (hESC) lines.  

"Of the more than 150 patents and patent applications related to stem cell therapy and regenerative medicine that ACT owns or licenses, this patent on our single-blastomere technology is one of the most significant," stated Gary Rabin, ACT's interim chairman and CEO.  "It will help us accelerate our progress on a number of fronts, including deriving embryonic stem cells which meet the regulatory standards of the European Medicines Agency and the US Food and Drug Administration, using the single-blastomere technology.  We are currently developing a collaboration for creating banks of these cells using our proprietary technique with the United Kingdom's Roslin Cells.  This is an example of the type of potentially revenue-generating future partnership that we think this IP (intellectual property) protection could help facilitate."

The single-blastomere technology uses a one-cell biopsy approach similar to pre-implantation genetic diagnosis (PGD), which is widely used in the in vitro fertilization (IVF) process and does not interfere with the embryo's developmental potential.  The stem cells generated using this approach are healthy, completely normal, and differentiate into all the cell types of the human body, including insulin-producing cells, blood cells, beating heart cells, cartilage, and other cell types of therapeutic importance.  The safety record for one-cell biopsy as part of PGD now has a 15-year track record, and is carried out routinely as part of IVF processes around the world.  ACT's "embryo-safe" technique has been published in been peer-reviewed journals such as Nature and Cell Stem Cell.

Robert Lanza, M.D., chief scientific officer of ACT, said, "This patent issuance represents recognition of the innovation underlying our single-blastomere technology.  In the US alone, over 100 people die every hour from diseases that could potentially benefit from this 'embryo-safe' technique.  Single cells are removed from the embryos, which remain healthy and continue to develop normally at rates consistent with whole (non-biopsied) embryos. Furthermore, this IP protection follows on the issuance of a broad patent relating to ACT's production and therapeutic use of Retinal Pigment Epithelial (RPE) cells in 2010. We are eagerly anticipating the start of the two Phase 1/2 clinical trials in the first half of this year.  Our RPE program uses hESCs derived from a single blastomere, and as such, this source of embryonic stem cells has been subjected to extensive regulatory scrutiny in order to demonstrate their safety and suitability to be used in human patients on a trial basis."

ACT has been issued clearance from the FDA to proceed with two Phase 1/2 clinical trials in the U.S. for its RPE program, including a Phase 1/2 trial in  patients with dry age-related macular degeneration.

About Advanced Cell Technology, Inc.Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit

Forward-Looking StatementsStatements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-K for the year ended December 31, 2009.  Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. There can be no assurance that the Company's clinical trials will be successful. Contact:Investors:CEOcast, Inc., James Young, 212-732-4300Press:ACT Corporate Communications, Bill Douglass, 646-450-3615or:Russo Partners, Martina Schwarzkopf, Ph.D., 212-845-4292

SOURCE Advanced Cell Technology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Progenitor Cell Therapy Secures Industry Accreditation
2. Althea Technologies Secures $12 M Credit Line to Continue Facility Growth and Expansion
3. Trillium secures additional financing on the strength of lead program and proprietary position around the CD200 immunoregulatory pathway
4. Northwest Secures US$1.0 Million Debt Financing
5. Transave, Inc. Secures $12.5 Million in New Financing
6. NeoStem Secures $250,000 in an Above Market Financing and Expands Its Relationship With New England Cryogenic Center, Inc.
7. Northwest Secures US$1.65 Million Debt Financing
8. Queens secures £25m for UKs cyber-safety
9. Queens secures £25M for UKs cyber safety
10. Interface Biologics secures $5mm financing and appoints Thomas P. Reeves President and Chief Executive Officer
11. EcoSphere(R) Biolatex(TM) Secures Funding from Granholm and Invest Michigan!
Post Your Comments:
(Date:11/25/2015)... , ... November 25, 2015 , ... ... uBiome, were featured on AngelList early in their initial angel funding process. Now, ... syndicate for individuals looking to make early stage investments in the microbiome space. ...
(Date:11/24/2015)... 2015 /CNW/ - iCo Therapeutics ("iCo" or "the Company") ... for the quarter ended September 30, 2015. Amounts, ... and presented under International Financial Reporting Standards ("IFRS"). ... said Andrew Rae , President & CEO ... not only value enriching for this clinical program, ...
(Date:11/24/2015)... PUNE, India , November 24, 2015 ... to a new market research report "Oligonucleotide Synthesis Market ... Equipment), Application (PCR, Gene Synthesis, Diagnostic, DNA, RNAi), End-User ... to 2020", published by MarketsandMarkets, the market is expected ... 1,078.1 Million in 2015, at a CAGR of 10.1% ...
(Date:11/24/2015)...  Tikcro Technologies Ltd. (OTCQB: TIKRF) today announced that its Annual General ... a.m. Israel time, at the law offices of ... 36 th Floor, Tel Aviv, Israel . ... Izhak Tamir to the Board of Directors; , election ... , approval of an amendment to certain terms of options granted to ...
Breaking Biology Technology:
(Date:11/11/2015)... Minn. , Nov. 11, 2015   MedNet Solutions ... entire spectrum of clinical research, is pleased to announce that ... in Clinical Trials (PCT) event, to be held November ... be able to view live demonstrations of iMedNet ... and learn how iMedNet has been able to ...
(Date:11/9/2015)... , Nov. 09, 2015 ... addition of the "Global Law Enforcement ... offering. --> ) has ... Law Enforcement Biometrics Market 2015-2019" report ... and Markets ( ) has announced ...
(Date:11/2/2015)... Calif. , Nov. 2, 2015  SRI International ... million to provide preclinical development services to the National ... contract, SRI will provide scientific expertise, modern testing and ... variety of preclinical pharmacology and toxicology studies to evaluate ... --> The PREVENT Cancer Drug Development Program ...
Breaking Biology News(10 mins):